Calcitonin gene related peptide receptor antagonists - Pfizer
Alternative Names: CGRP receptor antagonist-PfizerLatest Information Update: 27 May 2026
At a glance
- Originator Pfizer
- Class Antimigraines
- Mechanism of Action Calcitonin gene-related peptide receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Migraine
Most Recent Events
- 18 May 2026 Pfizer plans a phase I trial for Migraine (In volunteers) in Belgium (NCT07594769)
- 22 Apr 2026 Pfizer completes a phase I trial in Migraine (In volunteers) in USA (unspecified route) (NCT07261371)
- 24 Nov 2025 Phase-I clinical trials in Migraine (In volunteers) in USA (unspecified route) (NCT07261371)